The therapeutic and prognostic role of clusterin in diverse musculoskeletal diseases: a mini review

Title:

The therapeutic and prognostic role of clusterin in diverse musculoskeletal diseases: a mini review

Creator:

Zhang, Kun, Liu, Kaixin, Yu, Dechen, Tang, Yuchen, Geng, Bin, Xia, Yayi, and Xu, Peng

Identifier:

https://cdk.lib.cas.cz/client/handle/uuid:89916c68-eb32-4f0e-8968-7c2d78d99c09
uuid:89916c68-eb32-4f0e-8968-7c2d78d99c09
doi:10.33549/physiolres.934908

Subject:

clusterin, ischemic necrosis, spinal cord injury, osteoarthritis, osteosarcoma, rheumatoid arthritis, Brucella abortus, Sjogren's syndrome, idiopathic inflammatory myopathies, muscle glucose metabolism, insulin sensitivity, and trauma

Type:

model:article and TEXT

Format:

počítač and online zdroj

Description:

This mini-review aims to introduce the association between Secretory clusterin/apolipoprotein J (sCLU) and diverse musculoskeletal diseases. A comprehensive review of the literature was performed to identify basic science and clinical studies, which implied the therapeutic and prognostic role of sCLU in diverse musculoskeletal diseases. sCLU is a multifunctional glycoprotein that is ubiquitously expressed in various tissues and is implicated in many pathophysiological processes. Dysregulated expression of sCLU had been reported to be assocaited with proliferative or apoptotic molecular processes and inflammatory responses, which participated in many pathophysiological processes such as degenerative musculoskeletal diseases including ischemic osteonecrosis, osteoarthritis (OA) and degenerative cervical myelopathy (spinal cord injury), neoplastic musculoskeletal diseases, inflammatory and autoimmune musculoskeletal diseases including Rheumatoid arthritis (RA), joint damage induced by Brucella abortus, Sjogren's syndrome, idiopathic inflammatory myopathies, muscle glucose metabolism, insulin sensitivity and traumatic musculoskeletal diseases. Recent findings of sCLU in these musculoskeletal diseases provides insights on the therapeutic and prognostic role of sCLU in these musculoskeletal diseases. sCLU may serve as a promising therapeutic target for ischemic osteonecrosis, OA and spinal cord injury as well as a potential prognostic biomarker for OA and RA. Moreover, sCLU could act as a prognostic biomarker for osteosarcoma (OS) and a promising therapeutic target for OS resistance. Although many studies support the potential therapeutic and prognostic role of sCLU in some inflammatory and autoimmune-mediated musculoskeletal diseases, more future researches are needed to explore the molecular pathogenic mechanism mediated by sCLU implied in these musculoskeletal diseases.

Language:

English

Rights:

http://creativecommons.org/licenses/by-nc-sa/4.0/
policy:public

Coverage:

739-747

Source:

Physiological research | 2022 Volume:71 | Number:6

Harvested from:

CDK

Metadata only:

false